
==== Front
Ann Surg Oncol
Ann Surg Oncol
Annals of Surgical Oncology
1068-9265
1534-4681
Springer International Publishing Cham

39012458
15781
10.1245/s10434-024-15781-0
ASO Author Reflections
ASO Author Reflections: Von Willebrand Factor for Assessment of Portal Hypertension and Perioperative Risk in Resectable HCC
Pereyra D. MD, PhD 1
Mandorfer M. MD, PhD 23
Starlinger P. MD, PhD Starlinger.Patrick@mayo.edu

14
1 grid.411904.9 0000 0004 0520 9719 Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, General Hospital, Vienna, Austria
2 https://ror.org/05n3x4p02 grid.22937.3d 0000 0000 9259 8492 Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, General Hospital, Vienna, Austria
3 grid.411904.9 0000 0004 0520 9719 Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, General Hospital, Vienna, Austria
4 https://ror.org/02qp3tb03 grid.66875.3a 0000 0004 0459 167X Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN USA
16 7 2024
16 7 2024
2024
31 10 65846585
25 6 2024
25 6 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Medical University of ViennaOpen access funding provided by Medical University of Vienna.

issue-copyright-statement© Society of Surgical Oncology 2024
==== Body
pmcPast

Risk stratification for posthepatectomy liver failure (PHLF) is essential for optimizing outcome in patients undergoing liver resection. This is particularly important in patients treated for hepatocellular carcinoma (HCC) owing to their increased risk for postoperative complications from underlying advanced chronic liver disease (ACLD). The estimation of functional liver reserve is often imprecise owing to ACLD and portal hypertension, which represent significant challenges in preoperative risk assessment.1 Consequently, noninvasive but resource-intensive tests, such as indocyanine green clearance evaluation, along with minimally invasive hepatic venous pressure gradient measurement, which requires considerable expertise, remain essential components in the preoperative workup in this high-risk group.

Present

This retrospective analysis2 aimed to optimize preoperative risk assessment in HCC patients, using Von Willebrand factor antigen (vWF-Ag), a broadly available noninvasive biomarker for PHLF. vWF-Ag has previously been evaluated and validated for predicting PHLF in cohorts of all-comers for liver resection and displayed high diagnostic accuracy for clinically significant portal hypertension (CSPH) in patients with compensated ACLD.3,4 The present data facilitated the establishment of cutoffs for noninvasive CSPH assessment as well as PHLF risk stratification in patients with HCC. Moreover, associations of vWF-Ag with early disease recurrence and short overall survival in HCC patients were observed.

In the present study, which includes a large cohort of compensated and potentially resectable HCC patients, the applied cutoffs for vWF-Ag identified risk groups of particular clinical interest. A low-risk cutoff (vWF-Ag ≤ 182%) ruled out CSPH and showed a negative predictive value of 100% for PHLF. Thus, it identifies a subgroup of patients for whom additional resource-intensive preoperative evaluation can be safely omitted. In contrast, vWF-Ag levels of > 291% were indicative of CSPH; 57% of patients within this highest-risk group developed PHLF, and 50% of these patients did not survive the first postoperative year. The positive likelihood ratio for preoperative vWF-Ag > 291% of 6.05 indicates a substantial increase in the probability for PHLF from 20% (pre-test) to 60% (post-test). Importantly, the findings on PHLF risk were validated in an external cohort of HCC patients undergoing liver resection.

Future

The observations made in these well-characterized sets of HCC patients are highly relevant for clinical decision-making. As patient selection based on the individual risk for PHLF and disease recurrence is crucial for improving outcomes of HCC patients considered for liver resection, including vWF-Ag in the process of preoperative risk evaluation adds granularity to the current assessments. Notably, vWF-Ag helps define a low-risk cohort in which HVPG testing may not be necessary as the risk of CSPH is minimal and outcomes are excellent. Conversely, patients in the highest-risk group are unlikely to benefit from liver resection and may be better served by alternative treatment options, though the optimal plan of action requires further evaluation.5 In summary, use of vWF-Ag testing might ultimately allow for more individualized treatment of HCC patients, while also being a low-cost, noninvasive, and readily available biomarker.

Funding

Open access funding provided by Medical University of Vienna.

Disclosure

The authors have no conflicts of interest to disclose.

This article refers to: Pereyra D, Mandorfer M, Santol J, et al. Von Willebrand factor antigen improves risk stratification in patients diagnosed with resectable hepatocellular carcinoma. Ann Surg Oncol. (2024). 10.1245/s10434-024-15618-w.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Aliseda D Zozaya G Martí-Cruchaga P The impact of portal hypertension assessment method on the outcomes of hepatocellular carcinoma resection: a meta-analysis of matched cohort and prospective studies Ann Surg 2024 280 1 46 55 38126757
Aliseda D, Zozaya G, Martí-Cruchaga P, et al. The impact of portal hypertension assessment method on the outcomes of hepatocellular carcinoma resection: a meta-analysis of matched cohort and prospective studies. Ann Surg. 2024;280(1):46–55.38126757
2. Pereyra D Mandorfer M Santol J Von Willebrand factor antigen improves risk stratification in patients diagnosed with resectable hepatocellular carcinoma Ann Surg Oncol 2024 10.1245/s10434-024-15618-w 39012458
Pereyra D, Mandorfer M, Santol J, et al. Von Willebrand factor antigen improves risk stratification in patients diagnosed with resectable hepatocellular carcinoma. Ann Surg Oncol. 2024. 10.1245/s10434-024-15618-w.39012458
3. Mandorfer M Schwabl P Paternostro R Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity Aliment Pharmacol Ther 2018 47 7 980 988 10.1111/apt.14522 29377193
Mandorfer M, Schwabl P, Paternostro R, et al. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. Aliment Pharmacol Ther. 2018;47(7):980–8.29377193
4. Starlinger P Pereyra D Haegele S Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection Hepatology 2018 67 4 1516 1530 10.1002/hep.29651 29140542
Starlinger P, Pereyra D, Haegele S, et al. Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection. Hepatology. 2018;67(4):1516–30.29140542
5. Trevisani F Vitale A Kudo M Merits and boundaries of the BCLC staging and treatment algorithm: learning from the past to improve the future with a novel proposal J Hepatol 2024 80 4 661 669 10.1016/j.jhep.2024.01.010 38266658
Trevisani F, Vitale A, Kudo M, et al. Merits and boundaries of the BCLC staging and treatment algorithm: learning from the past to improve the future with a novel proposal. J Hepatol. 2024;80(4):661–9.38266658
